Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer
Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke
Аутори
Nedeljković, MilicaTanić, Nikola
Dramićanin, Tatjana
Milovanović, Zorka M.
Šušnjar, Snežana
Milinković, Vedrana
Vujović, Ivana
Tanić, Nasta
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
© 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MY...C copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.
Кључне речи:
c-MYC / copy number gain / FGFR1 / triple negative breast cancerИзвор:
Journal of Medical Biochemistry, 2018, 37, 2, 1-8Финансирање / пројекти:
- Идентификација молекуларних маркера за предикцију прогресије тумора, одговора на терапију и исхода болести (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41031)
- Молекуларне детерминанте за дизајн тумор маркера (RS-MESTD-Basic Research (BR or ON)-173049)
Колекције
Институција/група
VinčaTY - JOUR AU - Nedeljković, Milica AU - Tanić, Nikola AU - Dramićanin, Tatjana AU - Milovanović, Zorka M. AU - Šušnjar, Snežana AU - Milinković, Vedrana AU - Vujović, Ivana AU - Tanić, Nasta PY - 2018 UR - https://vinar.vin.bg.ac.rs/handle/123456789/7683 AB - © 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival. T2 - Journal of Medical Biochemistry T1 - Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer T1 - Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke VL - 37 IS - 2 SP - 1 EP - 8 DO - 10.1515/jomb-2018-0012 ER -
@article{ author = "Nedeljković, Milica and Tanić, Nikola and Dramićanin, Tatjana and Milovanović, Zorka M. and Šušnjar, Snežana and Milinković, Vedrana and Vujović, Ivana and Tanić, Nasta", year = "2018", abstract = "© 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.", journal = "Journal of Medical Biochemistry", title = "Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer, Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke", volume = "37", number = "2", pages = "1-8", doi = "10.1515/jomb-2018-0012" }
Nedeljković, M., Tanić, N., Dramićanin, T., Milovanović, Z. M., Šušnjar, S., Milinković, V., Vujović, I.,& Tanić, N.. (2018). Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. in Journal of Medical Biochemistry, 37(2), 1-8. https://doi.org/10.1515/jomb-2018-0012
Nedeljković M, Tanić N, Dramićanin T, Milovanović ZM, Šušnjar S, Milinković V, Vujović I, Tanić N. Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. in Journal of Medical Biochemistry. 2018;37(2):1-8. doi:10.1515/jomb-2018-0012 .
Nedeljković, Milica, Tanić, Nikola, Dramićanin, Tatjana, Milovanović, Zorka M., Šušnjar, Snežana, Milinković, Vedrana, Vujović, Ivana, Tanić, Nasta, "Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer" in Journal of Medical Biochemistry, 37, no. 2 (2018):1-8, https://doi.org/10.1515/jomb-2018-0012 . .